Document:

Exhibit 4.2

 

Global Security

 

THIS SECURITY IS A GLOBAL SECURITY WITHIN
THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS GLOBAL
SECURITY MAY NOT BE EXCHANGED, IN WHOLE OR IN PART, FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS GLOBAL SECURITY
IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN THE DEPOSITARY OR A NOMINEE THEREOF,
EXCEPT IN THE LIMITED CIRCUMSTANCES SET FORTH IN THE INDENTURE.

 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR
PAYMENT, AND ANY CERTIFICATE ISSUED IN EXCHANGE FOR THIS CERTIFICATE OR ANY PORTION HEREOF IS REGISTERED IN THE NAME OF CEDE &
CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT IS MADE
TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY),
ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON OTHER THAN THE DEPOSITORY TRUST COMPANY OR
A NOMINEE THEREOF IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

 

BEMIS COMPANY, INC.

 

2.630% GUARANTEED SENIOR NOTE DUE 2030

 

	CUSIP 081437AT2	     No. 1
	 	 
	ISIN US081437AT26	     US$500,000,000

 

BEMIS COMPANY, INC., a corporation organized
under the laws of Missouri (the “Issuer,” which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co., or its registered assigns, on June 19, 2030
(the “Stated Maturity”) the Initial Principal Amount specified on Schedule A hereto (such Initial Principal Amount,
as it may from time to time be adjusted by endorsement on Schedule A hereto, is hereinafter referred to as the “Principal
Amount”), or such other principal amount (which, when taken together with the principal amounts of all other Outstanding
Securities, shall initially equal US$500,000,000 in the aggregate) as may be set forth in the records of the Trustee hereinafter
referred to in accordance with the Indenture and to pay interest thereon from June 19, 2020 or from the most recent Interest
Payment Date to which interest has been paid or duly provided for, semi-annually on June 19 and December 19 in each year,
commencing December 19, 2020, at the rate of 2.630% per annum (computed on the basis of a 360-day year consisting of twelve
30-day months), until the Principal Amount hereof is paid or made available for payment. The interest so payable, and punctually
paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name
this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such
interest, which shall be the day that is 15 calendar days prior to each such Interest Payment Date (whether or not a Business Day).
Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular
Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered
at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice
whereof shall be given to Holders of Securities of this series not less than ten (10) days prior to such Special Record Date,
or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the
Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in
said Indenture.

 

     

     

    

 

Payment of the principal of (and premium,
if any) and interest on this Security will be made at the office or agency of the Issuer or Paying Agent maintained for that purpose
in the Borough of Manhattan, The City of New York, New York, in such coin or currency of the United States of America as at the
time of payment is legal tender for payment of public and private debts; provided, however, that at the option of the Issuer
payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the
Security Register; and provided, further, that notwithstanding the foregoing, payments of any interest on the Securities
(other than at Maturity) may be made, in the case of a Holder of at least US$10,000,000 Principal Amount of Securities, by electronic
funds transfer of immediately available funds to a United States dollar account maintained by the payee with a bank, provided
that such registered Holder shall have provided the Trustee written wire instructions at least fifteen (15) calendar days prior
to the applicable Interest Payment Date. Unless such designation is revoked by written notice to the Issuer or a Paying Agent,
any such designation made by such Holder with respect to such Securities will remain in effect with respect to any future payments
with respect to such Securities payable to such Holder. The Issuer will pay any administrative costs imposed by banks in connection
with making payments by electronic funds transfer.

 

In certain circumstances, Additional Amounts
will be payable in respect of this Security in accordance with terms of the Indenture. Whenever in this Security there is mentioned,
in any context, any payments on this Security such mention shall be deemed to include mention of the payment of Additional Amounts
to the extent that, in such context, Additional Amounts are, were or would be payable and express mention of the payment of Additional
Amounts in any provisions hereof shall not be construed as excluding Additional Amounts in those provisions hereof where such express
mention is not made.

 

Reference is hereby made to the further provisions
of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set
forth at this place.

 

This Security shall be entitled to the benefits
under the Indenture and be valid or obligatory for any purpose, unless the Securities have not been signed by the Issuer or the
certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature.

 

[Remainder of page left intentionally
blank.]

 

     

     

    

 

IN WITNESS WHEREOF, the Issuer has caused
this instrument to be duly executed.

 

Dated:

 

	The foregoing agreement is
    hereby	  )
	confirmed and accepted as of
    the	  )
	date first above written:	  )
	 	  )
	BEMIS COMPANY, INC.	  )
	 	  )
	 	  )
	 	  )  

 

	By:  	 	 )
	Name:	 )
	Title:	 )

    

[Signature
Page to Global Security]

 

     

     

    

 

CERTIFICATE OF AUTHENTICATION

 

This is one of the Securities referred to
in the within-mentioned Indenture.

 

Dated:

 

	 	DEUTSCHE
    BANK TRUST COMPANY AMERICAS, as Trustee
	 	 
	 	  By  	                  
	 	  Authorized
    Signatory

 

[Signature
Page to Global Security]

 

     

     

    

 

REVERSE OF SECURITY

 

This Security is one of a duly authorized
issue of securities of the Issuer (the “Securities”), issued and to be issued in one or more series under an Indenture,
dated as of June 19, 2020 (the “Indenture”), among the Issuer, the Guarantors party thereto and Deutsche Bank
Trust Company Americas, as Trustee, and reference is hereby made to the Indenture for a statement of the respective rights, limitations
of rights, duties and immunities thereunder of the Issuer, the Guarantors, the Trustee and the Holders of the Securities and of
the terms upon which the Securities are, and are to be, authenticated and delivered.

 

This Security is one of the series designated
on the face hereof; provided, however, that the Issuer may from time to time or at any time, without the consent of the
Holders of the Securities, create and issue additional Securities with terms and conditions identical to those of the Securities
(except for the issue date, the issue price and the first interest payment date), which additional Securities shall increase the
aggregate principal amount of, and shall be consolidated and form a single series with, the Securities; provided that if
such additional Securities are not fungible with the Securities for U.S. federal income tax purposes, such additional Securities
will have a different CUSIP number from the Securities.

 

This Security is an unsecured obligation of
the Issuer and ranks in right of payment on parity with all other unsecured and unsubordinated indebtedness of the Issuer (and
without any preference among themselves) and the Guarantees are unsecured obligations of the Guarantors and will rank on a parity
with all other unsecured and unsubordinated indebtedness of the Guarantors, except, in each case, for indebtedness mandatorily
preferred by law.

 

The Securities of this series are subject
to redemption at the option of the Issuer on any date prior to March 19, 2030 (any such date, a “Make-Whole Redemption
Date”), in whole or from time to time in part, at a redemption price equal to the greater of (1) 100% of the principal
amount of the Securities being redeemed and (2) the Make-Whole Amount for the Securities being redeemed, plus, in either case,
accrued and unpaid interest to such Make-Whole Redemption Date, all as provided in the Indenture. Notwithstanding the foregoing,
installments of interest on Securities that are due and payable on Interest Payment Dates falling on or prior to a Make-Whole Redemption
Date will be payable on the Interest Payment Date in accordance with their terms and in accordance with the provisions of the Indenture.

 

For the purposes of this Security:

 

“Adjusted Treasury Rate” means,
with respect to any Make-Whole Redemption Date, (a) the yield, under the heading which represents the average for the immediately
preceding week, appearing in the most recently published statistical release designated “H.15(519)” or any successor
publication, which is published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on
actively traded United States Treasury securities adjusted to constant maturity under the caption “Treasury Constant Maturities,”
for the maturity corresponding to the Comparable Treasury Issue (if no maturity is within three months before or after the remaining
term of the Securities being redeemed, yields for the two published maturities most closely corresponding to the Comparable Treasury
Issue shall be determined and the Adjusted Treasury Rate shall be interpolated or extrapolated from such yields on a straight line
basis, rounding to the nearest month) or (b) if such release (or any successor release) is not published during the week preceding
the calculation date or does not contain such yields, the rate per annum equal to the semi-annual equivalent yield to maturity
of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal
amount) equal to the Comparable Treasury Price for such Make-Whole Redemption Date, in each case calculated on the third Business
Day preceding the Make-Whole Redemption Date.

 

     

     

    

 

“Applicable Margin” means 0.300%.

 

“Comparable Treasury Issue” means
the United States Treasury security selected by the Quotation Agent as having a maturity comparable to the remaining term from
the Make-Whole Redemption Date to the maturity date of the Securities to be redeemed that would be utilized, at the time of selection
and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity
to the remaining term of the Securities.

 

“Comparable Treasury Price” means,
with respect to any Make-Whole Redemption Date, if clause (b) of the Adjusted Treasury Rate is applicable, (i) the average
of five Reference Treasury Dealer Quotations for such Make-Whole Redemption Date, after excluding the highest and lowest such Reference
Treasury Dealer Quotations, or (ii) if the Quotation Agent obtains fewer than five such Reference Treasury Dealer Quotations,
the average of all such quotations, provided that in no event may the Quotation Agent use fewer than three such quotations.

 

“Make-Whole Amount” means the
sum, as determined by a Quotation Agent, of (a) the present value of the principal amount of the Securities to be redeemed
and (b) the present value of the Remaining Scheduled Payments of interest thereon (not including any portions of such payments
of interest accrued to the Make-Whole Redemption Date), from the Make-Whole Redemption Date to the Stated Maturity of the Securities
being redeemed, in each case discounted to the Make-Whole Redemption Date on a semi-annual basis, assuming a 360-day year consisting
of twelve 30-day months, at the Adjusted Treasury Rate plus the Applicable Margin.

 

“Quotation Agent” means the Reference
Treasury Dealer selected by the Issuer, and notified in writing to the Trustee, to act as “Quotation Agent” for purposes
of this Indenture.

 

“Reference Treasury Dealer” means
(i) any of J.P. Morgan Securities LLC, BofA Securities, Inc., Citigroup Global Markets Inc. or Wells Fargo Securities,
LLC and their respective successors and assigns and (ii) two other nationally recognized investment banking firms selected
by the Issuer that are primary U.S. Government securities dealers in New York City (a “Primary Treasury Dealer”); provided,
however, that if any of J.P. Morgan Securities LLC, BofA Securities, Inc., Citigroup Global Markets Inc. or Wells Fargo Securities,
LLC shall cease to be a Primary Treasury Dealer, the Issuer shall substitute therefor another Primary Treasury Dealer.

 

“Reference Treasury Dealer Quotations”
means, with respect to each Reference Treasury Dealer and any Make-Whole Redemption Date, the average, as determined by the Quotation
Agent, of the bid and asked prices for the Comparable Treasury Issue, expressed in each case as a percentage of its principal amount,
quoted in writing to the Quotation Agent by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the third Business
Day preceding such Make-Whole Redemption Date.

 

     

     

    

 

“Remaining Scheduled Payments”
means, with respect to each Security to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon
at the then-applicable interest rate that would be due after the related Make-Whole Redemption Date but for such redemption, provided,
however, that, if that Make-Whole Redemption Date is not an Interest Payment Date with respect to such Security, the amount of
the next succeeding scheduled interest payment thereon shall be reduced by the amount of interest accrued thereon to that Make-Whole
Redemption Date.

 

On or after March 19, 2030, the Securities
are subject to redemption at the option of the Issuer on any date (a “Par Call Redemption Date”), in whole or from
time to time in part, at a redemption price equal to 100% of the principal amount of the Securities being redeemed, plus accrued
and unpaid interest to such redemption date, all as provided in the Indenture. Notwithstanding the foregoing, installments of interest
on Securities that are due and payable on Interest Payment Dates falling on or prior to a Par Call Redemption Date will be payable
on the Interest Payment Date in accordance with their terms and in accordance with the provisions of the Indenture.

 

In addition to its ability to redeem this
Security pursuant to the foregoing, this Security may be redeemed by the Issuer on the terms set forth, and as more fully described,
in Section 1108 of the Indenture, in certain circumstances where the Issuer would be required to pay Additional Amounts due
to certain changes in the tax treatment of this Security or the Guarantees.

 

In the event of redemption of this Security
in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in
the name of the Holder hereof upon the cancellation hereof.

 

Upon the occurrence of any Change of Control
Triggering Event and upon the terms and conditions set forth in Section 1009 of the Indenture, each Holder has the right to
require the Issuer to purchase all or a portion of the Securities of such Holder properly tendered at a purchase price equal to
101% of the principal amount thereof, plus accrued and unpaid interest (if any) to the date of purchase (subject to the right of
holders of record on the relevant record date to receive interest due on the relevant interest payment date).

 

The Indenture contains provisions for defeasance
at any time of the entire indebtedness of the series of which this Security is a part or certain restrictive covenants and Events
of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture.

 

If an Event of Default shall occur and be
continuing, the principal of the Securities may be declared due and payable in the manner and with the effect provided in the Indenture.

 

In any case where the due date for the payment
of the Principal Amount of, or any premium or interest with respect to any Security or the date fixed for redemption of any Security
shall not be a Business Day at a Place of Payment, then payment of the Principal Amount, premium, if any, or interest, including
any Additional Amounts payable in respect thereto need not be made on such date at such Place of Payment but may be made on the
next succeeding Business Day at such Place of Payment, with the same force and effect as if made on the date for such payment or
the date fixed for redemption, and no interest shall accrue for the period after such date.

 

     

     

    

 

The Indenture permits, with certain exceptions
as therein provided, the amendment thereof and the modification of the rights and obligations of the Issuer and the Guarantors
and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Issuer, the
Guarantors, and the Trustee with the consent of the Holders of a majority in Principal Amount of the Securities at the time Outstanding
of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in Principal
Amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to
waive compliance by the Issuer, the Guarantors, or any of them, with certain provisions of the Indenture and certain past defaults
under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding
upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof
or in exchange therefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

 

The Guarantors that are a party to the Indenture
as at, or subsequent to, the date of authentication of this Security (including any New Guarantors in accordance with Section 1010
of the Indenture and subject to release of any Subsidiary Guarantor(s) in accordance with Section 1302 of the Indenture),
have fully, unconditionally and irrevocably guaranteed, on a joint and several basis, pursuant to the terms of the Guarantees contained
in Article Thirteen of the Indenture, the due and punctual payment of the principal of and any premium and interest on this
Security, any Additional Amounts payable in respect thereof and any other amounts payable by the Issuer under the Indenture, when
and as the same shall become due and payable, whether at the Stated Maturity, by declaration of acceleration, call for redemption
or otherwise, in accordance with the terms of this Security and the Indenture. The obligations of the Guarantors to the Holder
of this Security and to the Trustee pursuant to the Guarantees and the Indenture are expressly set forth in Article Thirteen
of the Indenture and reference is made to such Article and Indenture for the precise terms of the Guarantees.

 

Within 30 days of any Subsidiary of the Parent
Guarantor becoming a Relevant Guarantor, the Parent Guarantor shall cause such Relevant Guarantor to also become a Guarantor (each,
a “New Guarantor”) of all amounts due and owing on the Outstanding Securities by having such New Guarantor, the Issuer
and the Trustee deliver a New Guarantor Supplemental Indenture within such 30 day period, provided that such New Guarantor’s
Guarantee may contain any limitation required under the laws of the jurisdiction in which it is incorporated or organized, or which
are substantially similar to the limitations contained in such other new guarantees given by the New Guarantor in relation to the
Specified Indebtedness giving rise to its status as a Relevant Guarantor.

 

Upon execution and delivery by the New Guarantor
of its New Guarantor Supplemental Indenture and any other documents provided for in Section 1010, the New Guarantor shall
be a Guarantor for the purposes of this Indenture and for purposes of all amounts due and owing on the Outstanding Securities.
In connection therewith, (i) the rights and obligations of such New Guarantor and the restrictions imposed upon it under this
Indenture shall be the same in all respects as if the New Guarantor had been an Original Guarantor and (ii) the rights and
obligations and restrictions imposed upon the other Guarantors shall be the same in all respects as if the New Guarantor had been
an Original Guarantor.

 

     

     

    

 

In accordance with Section 1302 of the
Indenture, any or all of the Subsidiary Guarantors may be released at any time from their respective Guarantees and other obligations
under the Indenture and the Securities without the consent of any Holder. Such release will occur upon or concurrently with the
Subsidiary Guarantor no longer being a Relevant Guarantor and upon the delivery of an Officer’s Certificate of Release to
the Trustee certifying that the Subsidiary Guarantor is no longer a Relevant Guarantor, provided that, at the time of such
release, no default or Event of Default has occurred and is continuing.

 

As provided in and subject to the provisions
of the Indenture, the Holder of this Security shall not have the right to institute any proceeding, judicial or otherwise, with
respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder
shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this
series, the Holders of not less than 25% in aggregate principal amount of the Securities of this series at the time Outstanding
shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered
the Trustee indemnity satisfactory to it, and the Trustee shall not have received from the Holders of a majority in aggregate principal
amount of Securities of this series at the time Outstanding a direction inconsistent with such request, and the Trustee shall have
failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing
shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal amount hereof
or any premium or interest hereon on or after the respective due dates expressed herein.

 

No reference herein to the Indenture and no
provision of this Security or of the Indenture shall alter or impair the obligation of the Issuer or the Guarantors, which is absolute
and unconditional, to pay the principal amount of and any premium and interest on this Security at the times, place and rate, and
in the coin or currency, herein prescribed.

 

As provided in the Indenture and subject to
certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of
this Security for registration of transfer at the office or agency of the Issuer in any place where the principal amount of and
any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in
form satisfactory to the Issuer and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized
in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the
same aggregate principal amount, will be issued to the designated transferee or transferees.

 

The Securities of this series are issuable
only in fully registered form, without coupons, and in minimum denominations of US$2,000 and any integral multiple of US$1,000
in excess thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series
are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a different authorized
denomination, as requested by the Holder surrendering the same.

 

     

     

    

 

No service charge shall be made for any such
registration of transfer or exchange, but the Issuer may require payment of a sum sufficient to cover any tax or other governmental
charge payable in connection therewith.

 

Prior to due presentment of this Security
for registration of transfer, the Issuer, the Trustee and any agent of the Issuer, the Guarantors or the Trustee may treat the
Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security is overdue,
and none of the Issuer, the Trustee nor any such agent shall be affected by notice to the contrary.

 

This Security and the Guarantees shall be
governed by and construed in accordance with the law of the State of New York, but without regard to the principles of conflicts
of laws thereof that would require the application of the laws of a jurisdiction other than the State of New York; provided,
however, that all matters governing the authorization and execution of the Securities by the Issuer shall be governed by and construed
in accordance with the laws of the State of Missouri and the authorization and execution of any notation of the Guarantees by the
Guarantors pursuant to Article Thirteen of the Indenture or any Guarantees endorsed by such Guarantors on this Security, if
any, shall be governed by and construed in accordance with the laws of the respective places of incorporation of each such Guarantor.

 

All terms used in this Security are defined
in the Indenture shall have the meanings assigned to them in the Indenture.

 

     

     

    

 

Schedule A

 

By purchasing this Security, the Holder hereby agrees to the
terms set forth in the Indenture.

 

SCHEDULE OF ADJUSTMENTS

 

Initial Principal Amount: US$500,000,000

 

	Date

 adjustment 

made	 	Principal 

amount

 increase	 	Principal

 amount

 decrease	 	Principal

 amount

 following 

adjustment	 	Notation made

 on behalf of the

 Security 

RegistrarEX-10.15

 Exhibit 10.15 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 EXECUTION VERSION 

LICENSE AGREEMENT 

This LICENSE AGREEMENT (the “Agreement”) is made and entered into
effective as of October 24, 2019 (the “Effective Date”), by and between GENUS ONCOLOGY, LLC, a Delaware limited liability company (“Genus”), having a place of business at
650 Albany Street, Boston, MA 02118, and POSEIDA THERAPEUTICS, INC., a Delaware corporation (“Poseida”), having a place of business at 4242 Campus Point Court, Suite 700, San
Diego, CA 92121. Genus and Poseida are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 

WHEREAS, Genus has developed or otherwise controls certain intellectual property related to antibodies targeting mucin
1, cell surface associated (as defined below, “MUC1”); 
 WHEREAS, Poseida is a biopharmaceutical company
engaged in the development of gene and cell therapies for cancer and other disorders, including chimeric antigen receptor T cells and NK cells; and 

WHEREAS, Genus desires to grant Poseida an exclusive license, and Poseida desires to obtain from Genus an exclusive
license, to develop and commercialize CAR cells expressing antibodies and derivatives thereof targeting MUC1, on the terms and conditions set forth in this Agreement. 

NOW THEREFORE, in consideration of the foregoing and the covenants and promises contained herein, the
parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used
herein, the following terms shall have the following meanings: 
 1.1    “Acquirer” means,
collectively: (a) any Third Party that, after the closing of a change of control, controls Genus; and (b) such Third Party’s Affiliates existing immediately prior to the closing of such change of control. For the purposes of this
definition, change of control means (a) a merger, reorganization or consolidation of Genus with or into a Third Party which results in the voting securities of Genus outstanding immediately prior thereto ceasing to represent at least fifty
percent (50%) of the combined voting power of the surviving entity or the ultimate parent of the surviving entity immediately after such merger, reorganization or consolidation, (b) a Third Party becoming the beneficial owner of fifty percent
(50%) or more of the combined voting power of the outstanding securities of Genus other than as a result of a bona fide financing transaction of Genus or (c) the sale or other transfer to a Third Party of all or substantially all of
Genus’s business or assets to which this Agreement relates. 
 1.2    “Affiliate” means,
with respect to a particular Party, a person, corporation, partnership or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word “control” (including, with
correlative meaning, 

  
 1. 

 
the terms “controlled by” or “under common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the
direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity or by contract or otherwise. 

1.3    “Antibody” means (a) any sequence of the variable region of the light chain or the
heavy chain of any antibody that (i) is claimed or disclosed in any of the Patents set forth on Exhibit A or (ii) targets MUC1 and is Controlled by Genus or its Affiliates at any time during the Term, (b) any fragment,
derivative or modification of any of the foregoing that targets MUC1, including any recombinant version, chimera or humanized derivative, or fusion or conjugate with any other molecule, and that is claimed or disclosed in any Patent Controlled by
Genus, or (c) any nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid encoding) any one of the molecules described in the preceding clauses (a) or (b), where such nucleotide is claimed or
disclosed in any Patent Controlled by Genus. 
 1.4    “BLA” means (a) a Biologics License
Application filed with the FDA for marketing approval of a Licensed Cell Product, or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, and (b) similar filings outside
the United States with applicable Regulatory Authorities, including the EMA. BLA excludes pricing and reimbursement approvals. 

1.5    “Calendar Quarter” means a period of three (3) consecutive months corresponding to the
calendar quarters commencing on the first day of January, April, July, or October, or any partial period thereof immediately following the Effective Date or immediately prior to the termination or expiration of this Agreement. 

1.6    “Calendar Year” means a period of twelve (12) consecutive months corresponding to the
calendar year commencing on the first day of January, or any partial period thereof immediately following the Effective Date or immediately prior to the termination or expiration of this Agreement. 

1.7    “CAR” means a genetically engineered molecule that, when present on the surface of human
cells, enables such cells to recognize and bind to specific antigens that are present on the surface of other cells and that includes at least: (a) [...***...], (b) [...***...] and (c) [...***...]. 

1.8    “CAR Cell” means any cell, including without limitation a
T-lymphocyte or natural killer cell, that expresses or is capable of expressing a transgene encoding a CAR. 

1.9    “Combination Product” means a product in which [...***...] (each, an
“Other Product”) that are [...***...]. 
 1.10    “Commercially Reasonable
Efforts” means, with respect to the efforts to be expended by Poseida to develop or commercialize a Licensed Product, the level of efforts and expenditure of resources [...***...] 

 
 ***Certain Confidential Information Omitted 

  
 2. 

 [...***...]. 

1.11    “Confidential Information” means, with respect to a Party, all Information of such
Party (in such capacity, the “Disclosing Party”) that is disclosed to the other Party (in such capacity, the “Receiving Party”) in connection with this Agreement, whether disclosed in oral, written, graphic or
electronic form. All information disclosed by a Party pursuant to the Mutual Non-Disclosure Agreement between the Parties dated July 1, 2015 (the “Confidentiality Agreement”) shall be
deemed to be such Party’s Confidential Information hereunder. 
 1.12    “Control” means,
with respect to any material, Information or intellectual property right, that a Party (a) owns or (b) has a license (other than a license granted to such Party under this Agreement) to such material, Information or intellectual property
right and, in each case, has the ability to grant to the other Party access, a license or a sublicense (as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing
agreement or other legally enforceable arrangement with any Third Party. 
 1.13    “Cover”
means, with respect to a claim of a Patent in any country in the Territory and a Licensed Product, that such claim would (or, with respect to a claim in a pending patent application, would if such claim were to issue with the then-pending claims) be
infringed, absent a license thereunder or ownership thereof, by the manufacture, use, offer for sale, sale or importation of such Licensed Product, including the Antibody in such Licensed Product, in such country. 

1.14    “Covering Claim” has the meaning set forth in Section 4.4(b). 

1.15    “DFCI” means Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization. 
 1.16    “DFCI Agreement” means
that certain License and Exclusive Sublicense Agreement dated April 10, 2007, as amended prior to the Effective Date or thereafter in accordance with the terms of this Agreement, by and between DFCI and Genus. The DFCI Agreement, as in
existence as of the Effective Date, is attached hereto as Exhibit B. 
 1.17    “DFCI Patents”
means any and all Licensed Patents that are licensed to Genus by DFCI under the DFCI Agreement. 

1.18    “Disclosing Party” has the meaning set forth in Section 1.11. 

 
 ***Certain Confidential Information Omitted 

  
 3. 

 1.19    “Dollar” means a U.S. dollar, and
“$” shall be interpreted accordingly. 
 1.20    “EMA” means the European
Medicines Agency or any successor entity. 
 1.21    “FDA” means the United States Food
and Drug Administration or any successor entity. 
 1.22    “Field” means use of CAR Cells for
treatment, prevention and palliation of human diseases and conditions. 
 1.23    “First Commercial
Sale” means, with respect to a Licensed Product and regulatory jurisdiction, the first transfer to a Third Party of such Licensed Product in such regulatory jurisdiction after Regulatory Approval has been obtained in such jurisdiction for
such Licensed Product for which Net Sales are generated. 
 1.24    “GLP” means the then-current
good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58. 

1.25    “Governmental Authority” means any multi-national, federal, state, local, municipal,
provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.26    “Indication” means a human disease or medical condition that is approved by a Regulatory
Authority to be included as a discrete claim (as opposed to a subset of a claim) in the labeling of a Licensed Product based on: [...***...]. 

1.27    “Information” means any data, results and information of any type whatsoever, in any
tangible or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations, formulae, materials or compositions of matter
of any type or kind (patentable or otherwise), software, algorithms, marketing reports, expertise, stability, technology, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and
quality control data, stability data, studies and procedures. 
  

***Certain Confidential Information Omitted 

  
 4. 

 1.28    “Initiation” means, with respect to a
clinical trial, first dosing of the first subject in such clinical trial. 
 1.29    “Initiation of GLP
Tox” means the first dosing of an animal in the first non-clinical study of a Licensed Cell Product conducted in accordance with GLP. 

1.30    “Joint Inventions” has the meaning set forth in Section 6.1. 

1.31    “Joint Patents” has the meaning set forth in Section 6.1. 

1.32    “Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements
having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 

1.33    “Licensed Cell Patent” means a Licensed Patent that Covers a Licensed Cell Product. 

1.34    “Licensed Know-How” means all Information that is:
(a) Controlled by Genus or its Affiliates (excluding an Acquirer) as of the Effective Date or during the Option Period; (b) disclosed to Poseida prior to [...***...] days after Poseida’s exercise of the Option; and
(c) necessary to develop, manufacture or commercialize any Licensed Product, but excluding the Joint Inventions. 

1.35    “Licensed Patent” means any Patent that: (a) is Controlled by Genus or its
Affiliates, as of the Effective Date or at any time during the Term; provided however, Licensed Patent excludes any Patent Controlled by an Acquirer that that is not an improvement or modification of any Patent Controlled by Genus or its Affiliates
immediately prior to the closing of the change of control; and (b) Covers development, manufacture, use, sale, offer for sale, or import of any Licensed Product, but excluding the Joint Patents. Licensed Patents include all Patents listed on
Exhibit A. 
 1.36    “Licensed Product” means (a) a product that
incorporates, uses or administers a CAR Cell, alone or with one or more other active ingredients (a “Licensed Cell Product”) or (b) any diagnostic device, assay or test performed for the purpose of providing diagnostic or other
information to determine whether use of a Licensed Cell Product is appropriate, safe or effective for a particular disease or condition (a “Licensed Companion Diagnostic”). 

1.37    “Licensed Technology” means the Licensed Patents, the Licensed Know-How and Genus’ interest in the Joint Inventions and Joint Patents. 

1.38    “Major Market” means any of the [...***...]. 

1.39    “MUC1” means mucin 1, a transmembrane mucin family protein consisting of highly conserved
20 amino acid repeats (HGVTSAPDTRPAPGSTAPPA) decorated with a dense O-linked glycosylation pattern. 
  

***Certain Confidential Information Omitted 

  
 5. 

 1.40    Net Sales.  
 (a)    “Net Sales” means, with respect to any
Licensed Product, the gross income derived by Poseida and its Affiliates and Sublicensees for sales or transfer of such Licensed Product in the Field to unaffiliated Third Parties (including distributors and end users), less the following deductions
to the extent such deductions (A) are borne by Poseida, its Affiliates or Sublicensees and (B) are consistent with the accounting standards of the selling Person: 
  

	 	(i)	 [...***...]; 

  

	 	(ii)	 [...***...]; 

  

	 	(iii)	 [...***...]; 

  

	 	(iv)	 [...***...]; 

  

	 	(v)	 [...***...]; and 

 

	 	(vi)	 [...***...]. 

Net Sales includes the fair market value of any non-cash consideration from sale of Licensed Products
received by Company, its Affiliates or Sublicensees. 
 Licensed Products are considered “sold” or “transferred” when
billed, invoiced, or payment is received, whichever occurs first. 
 Notwithstanding the foregoing, amounts received or invoiced by Poseida
or its Affiliates or Sublicensees for the sale of Licensed Products among Poseida and its Affiliates and Sublicensees shall not be included in the computation of Net Sales hereunder. 

 
 ***Certain Confidential Information Omitted 

  
 6. 

 Notwithstanding the foregoing, Net Sales shall not include any amounts invoiced for sales of
Licensed Products supplied for use in clinical trials, or under early access, compassionate use, named patient, indigent access, patient assistance or other similar reduced pricing programs. 

(b)    In the event a Licensed Product is sold as part of a Combination Product, Net Sales for the purposes of determining
payments hereunder shall be calculated as follows: 
  

	 	(i)	 [...***...]. 

  

	 	(ii)	 [...***...]. 

  

	 	(iii)	 [...***...]. 

  

	 	(iv)	 [...***...]. 

  

	 	(v)	 [...***...]. 

1.41    “Option” has the meaning set forth in Section 2.1(a). 

1.42    “Option Period” means the period of time commencing on the Effective Date and ending
[...***...] thereafter. 
  
 ***Certain Confidential Information
Omitted 

  
 7. 

 1.43    “Patents” means
(a) pending patent applications, issued patents, utility models and designs; (b) reissues, substitutions, registrations, validations, re-examinations, continuations, continued prosecution
applications, continuations-in-part or divisions of or to any of the foregoing; and (c) extensions, renewals or restorations of any of the foregoing by existing or
future extension, renewal or restoration mechanisms, including supplementary protection certificates or the equivalent thereof. 

1.44    “Person” means an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization. 

1.45    “Phase 2 Clinical Trial” means a study in humans of the safety, dose range and efficacy of
a Licensed Cell Product that is designed to generate sufficient data to commence a Phase 3 Clinical Trial pursuant to 21 C.F.R. 312.21 or corresponding provision outside the United States. 

1.46    “Phase 3 Clinical Trial” means a clinical trial on a sufficient number of patients that is
designed to establish that a Licensed Cell Product is safe and efficacious for its intended use, or to define warnings, precautions and adverse reactions that are associated with the Licensed Cell Product in the dosage range to be prescribed, and to
support Regulatory Approval of such Licensed Cell Product. 
 1.47    “Pricing Approval” means
such governmental approval, agreement, determination or decision establishing prices for a Licensed Product that can be charged and/or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the
price and/or reimbursement of pharmaceutical products. 
 1.48    “Product Infringement” has the
meaning set forth in Section 6.3(a). 
 1.49    “Receiving Party” has the meaning set forth
in Section 1.11. 
 1.50    “Regulatory Approval” means all approvals, including, if
applicable, Pricing Approvals, that are necessary for the commercial sale of a Licensed Product in the Field in a given country or regulatory jurisdiction. 

1.51    “Regulatory Authority” means, in a particular country or jurisdiction, any applicable
Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction. 

1.52    “Regulatory Exclusivity” means any exclusive marketing rights conferred by any Regulatory
Authority with respect to a pharmaceutical product other than Patents, including orphan drug exclusivity, new chemical entity exclusivity or pediatric exclusivity. 

1.53    “Representatives” means directors, employees, officers, consultants and/or agents of the
specified Person. 
 1.54    “Royalty Term” has the meaning set forth in Section 4.4(b).

  
 8. 

 1.55    “Sublicensee” means a Third Party that
has received a sublicense from Poseida for some or all of the rights granted to Poseida under Section 2.2(b). 

1.56    “Term” has the meaning set forth in Section 10.1. 

1.57    “Territory” means all countries of the world. 

1.58    “Third Party” means a person or entity other than Genus or Poseida or their respective
Affiliates. 
 1.59    “United States” or “U.S.” means the United States of
America, including its territories and possessions. 
 1.60    “Valid Claim” means (a) a
claim of an issued and unexpired patent that has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within
the time allowed for appeal, and that has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a claim of a
pending patent application that has been pending less than five (5) years from the earliest date on which such patent application claims priority (direct or indirect, in whole or in part) and which claim was filed and is being prosecuted in
good faith and has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken. 

ARTICLE 2 

OPTION AND LICENSE GRANT 

2.1    Option 

(a)    Grant. Subject to the terms and conditions of this Agreement, Genus hereby grants to Poseida an exclusive
option during the Option Period to obtain the exclusive license set forth in Section 2.2(b) (the “Option”). 

(b)    Exercise. Poseida may exercise the Option by providing written notice to Genus delivered at any time during
the Option Period, and simultaneously paying to Genus the Option exercise fee pursuant to Section 4.2. 

2.2    Licenses to Poseida. 

(a)    During the Option Period. Subject to the terms and conditions of this Agreement, Genus hereby grants to
Poseida, during the Option Period, a non-exclusive, non-transferable (except in accordance with Section 12.10) license under the Licensed Technology to research,
develop, make, use, import and have made Licensed Products in the Field in the Territory, solely for purposes of development of Licensed Products and preparation for clinical trials, but in 

  
 9. 

 
no event does this license include the right for Poseida to initiate a clinical trial or commercialize any Licensed Products. Poseida may grant sublicenses under such license only to its
Affiliates and to Third Parties performing activities for or on behalf of Poseida. 
 (b)    Upon Option
Exercise. Subject to the terms and conditions of this Agreement, effective upon Poseida’s exercise of the Option pursuant to Section 2.1(b), Genus hereby grants to Poseida: (i) an exclusive (even as to Genus), non-transferable (except in accordance with Section 12.10), royalty bearing license, with the right to grant sublicenses through multiple tiers (subject to Section 2.3), under the Licensed Patents and
Joint Patents to research, develop, make, have made, use, import, offer for sale and sell Licensed Cell Products in the Field in the Territory; (ii) a non-exclusive,
non-transferable (except in accordance with Section 12.10), royalty bearing license, with the right to grant sublicenses through multiple tiers (subject to Section 2.3), under the Licensed Patents
and Joint Patents to research, develop, make, have made, use, import, offer for sale and sell Licensed Companion Diagnostics in the Field in the Territory; and (iii) a non-exclusive, non-transferable (except in accordance with Section 12.10), royalty bearing license, with the right to grant sublicenses (subject to Section 2.3), under the Licensed
Know-How and Joint Inventions, to research, develop, make, have made, use, import, offer for sale and sell Licensed Products in the Field in the Territory. 

2.3    Sublicenses. Poseida shall have the right to grant sublicenses through multiple tiers under any or
all of the rights granted in Section 2.2(b) to its Affiliates and to Third Parties, provided that Poseida shall notify DFCI [...***...] days prior to the execution of any further sublicense of the DFCI Patents under this Section 2.3
(a “DFCI Sublicense”). Genus shall provide all reasonable assistance to Poseida to provide such notification to DFCI. Each such sublicense shall be consistent with and subject to the terms and conditions of this Agreement, and
Poseida remains responsible for the operations of any Sublicensee under this Agreement as if the operations were carried out by Poseida. 

(a)    Notice. Poseida shall promptly notify Genus in writing of the identity of any prospective Sublicensee at
least [...***...] days prior to entering into a sublicense. 
 (b)    Form and Content of Sublicenses.
Poseida will issue any sublicenses granted by it under this Agreement in writing. Poseida will attach a copy of the DFCI Agreement to any DFCI Sublicense. In the event that Genus terminates this Agreement pursuant to Section 10.3, each
sublicense granted by Poseida to a Third Party will be treated in accordance with Section 10.4(b). Poseida shall include the equivalent of at least the following provisions in all sublicenses: 

(i)    Sublicensee shall use [...***...] efforts to diligently pursue the commercialization of the Licensed
Patents, consistent with the obligations of Poseida under this Agreement, and shall report annually to Poseida on its operations under the sublicense; 

(ii)    Sublicensee shall make payments due to Poseida in relation to Net Sales of Licensed Products in a timely manner,
so that Poseida may comply with Article 4 of this Agreement; and 
  

***Certain Confidential Information Omitted 

  
 10. 

 (iii)    With respect to DFCI Sublicenses, the following provisions of
the DFCI Agreement: Paragraph 2.5 (Reserved Rights), Paragraph 2.6 (Sublicensing), Sections 5.2.1 (Books and Records) and 5.2.2 (Inspections), Paragraphs 6.2 – 6.6 (U.S. Manufacture, Other Government Laws, Patent Marking, Publicity – Use
of Name, Confidentiality), Article 7 (Patent Preparation, Filing, Prosecution and Maintenance), Article 8 (Patent Infringement and Enforcement), Section 9.5.4 (Termination – Sublicenses), Article 10 (Indemnification, Defense and
Insurance), Article 11 (Warranties), and Article 14 (Dispute Resolution). 
 (c)    Copies of Sublicenses to
Genus. Poseida shall forward to Genus a copy of any and all fully executed sublicenses, provided that Poseida may redact any terms thereof that are not necessary to ensure compliance with the terms of this Agreement or the DFCI Agreement. Such
copy shall be postmarked within [...***...] days of the execution of the sublicense. Poseida shall also forward to Genus annually a copy of the reports received by Poseida from all Sublicensee(s) during the preceding [...***...] month
period under the sublicenses as shall be pertinent to (i) its operations under the Sublicense, and (ii) a royalty accounting under the sublicense. All such copies will be Poseida’s Confidential Information. 

(d)    Ongoing Obligations. Nothing in this Section 2.3 may be construed to relieve Poseida of its obligations
to Genus under this Agreement. 
 2.4    No Implied Licenses. Except as explicitly set forth in this
Agreement, neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party. Poseida acknowledges and agrees that the DFCI Patents are licensed to Genus by
DFCI under that certain DFCI Agreement. Poseida agrees that, notwithstanding any exclusive license granted to Poseida under this Agreement, (a) DFCI retains rights under the DFCI Patents as set forth in Section 2.5, and (b) any
licenses and rights granted by Genus to Poseida under the DFCI Patents are granted only within the permissible scope of sublicenses granted under the DFCI Agreement. 

2.5    Reserved Rights. The licenses granted by Genus under the DFCI Patents are subject to the following
reserved rights: 
 (a)    The rights of the United States of America, as set forth in Public Laws 96-517 and 98-620, the regulations promulgated thereunder, and the policy of any funding agencies. Any rights granted hereunder, which are greater than permitted by Public
Laws 96-517 and 98-620, are subject to modifications as required to conform to the provisions of those statutes. 

(b)    DFCI’s right to make and use the Licensed Intellectual Property defined in the DFCI Agreement (the
“DFCI Licensed Intellectual Property”) in the Field solely for teaching, education and other non-commercial research purposes, both laboratory and clinical. 

(c)    The rights of other academic, governmental or
not-for-profit organizations to use DFCI Licensed Intellectual Property solely for non-commercial research purposes in the Field.

  
 ***Certain Confidential Information Omitted 

  
 11. 

 (d)    DFCI’s right to grant
non-exclusive, non-transferable licenses under the DFCI Patents to other academic, governmental or
not-for-profit organizations to make and use DFCI Licensed Intellectual Property solely for non-commercial research purposes in
the Field. 
 Provided that with respect to rights reserved under this Section 2.5, DFCI has agreed that: (i) any rights under the DFCI Licensed
Intellectual Property granted to a Third Party shall be pursuant to a Material Transfer Agreement substantially in the form as shown on Schedule 9 to the DFCI Agreement and (ii) no rights will be granted to Third Parties to commercialize
products Covered by the DFCI Patents. 
 2.6    Upstream License Terms. Poseida acknowledges and
agrees that the rights and licenses granted under this Agreement with respect to the DFCI Patents are subject to the following provisions of the DFCI License Agreement (the “Upstream License Required Terms”): Paragraph 2.5 (Reserved
Rights), Paragraph 2.6 (Sublicensing), Sections 5.2.1 (Books and Records) and 5.2.2 (Inspections), Paragraphs 6.2 – 6.6 (U.S. Manufacture, Other Government Laws, Patent Marking, Publicity – Use of Name, Confidentiality), Article 7 (Patent
Preparation, Filing, Prosecution and Maintenance), Article 8 (Patent Infringement and Enforcement), Section 9.5.4 (Termination – Sublicenses), Article 10 (Indemnification, Defense and Insurance), Article 11 (Warranties), and Article 14
(Dispute Resolution). In the event of any inconsistency with the terms of this Agreement and the Upstream License Required Terms with respect to the DFCI Patents, the Upstream License Required Terms will control. 

2.7    U.S. Manufacture. Poseida shall manufacture Licensed Products Covered by DFCI Patents (“DFCI
Products”) leased, used, or sold in the United States substantially in the United States as required by 35 U.S.C. § 204 and 37 C.F.R. § 401 et seq., as amended, unless a waiver of such requirement is obtained. Genus will
reasonably assist Poseida in obtaining any such waiver. Poseida shall require any Affiliate(s) or Sublicensee(s) to comply with the U.S. manufacture requirement(s). 

2.8    Other Government Laws. Poseida shall comply with, and ensure that its Affiliates and Sublicensees
comply with, all applicable government statutes and regulations that relate to Licensed Products. 

2.9    Patent Marking. Poseida shall mark, and shall require its Sublicensees and Affiliates to mark, all
DFCI Products sold in the United States with the word “Patent” and the number or numbers of DFCI Patents applicable to the DFCI Product. 

2.10    Publicity – Use of Name (DFCI). Except as required by applicable law or regulation, Poseida,
its Affiliates and Sublicensees are not permitted to use the names of DFCI, its related entities or its employees, or any adaptation thereof, in any advertising, promotional or sales literature, or in any securities report required by the Securities
and Exchange Commission (except as required by law), without the prior written consent of DFCI. To the extent relevant to the rights granted to Poseida under the DFCI Patents, Poseida may: (a) refer to publications in the scientific literature
by employees of DFCI; or (b) state that a sublicense from DFCI has been granted as provided in this Agreement. 

  
 12. 

 2.11    Compliance with DFCI Agreement. 

(a)    Genus shall not take (or fail to take) any action, including failure to pay any amounts when due, that constitutes a
breach of the DFCI Agreement. Genus shall not, without the prior written consent of Poseida, take (or fail to take) any action with respect to the DFCI Agreement (including amending, terminating or otherwise modifying) that would reasonably be
expected to diminish the rights granted to Poseida under this Agreement. 
 (b)    Genus shall use [...***...]
efforts to enforce its rights and DFCI’s obligations under the DFCI Agreement to the extent required for Poseida to exercise its rights with respect to the DFCI Patents under this Agreement. 

(c)    Genus shall not assign (except an assignment to a party to which this Agreement has been assigned as permitted
under Section 12.10) the DFCI Agreement without the prior written consent of Poseida, not to be unreasonably withheld. 

(d)    Genus shall provide Poseida with prompt written notice of any written allegation of breach or notice of termination
of the DFCI Agreement, made by any of Genus, its Affiliate or DFCI. 
 (e)    In the event that Genus or its Affiliate
receives written notice of an alleged breach by Genus or its Affiliate under the DFCI Agreement, where termination of the DFCI Agreement or any diminishment of the licenses granted to Poseida under the DFCI Patents is being or could be sought by
DFCI, then Genus will promptly provide to Poseida written notice thereof as well as whether Genus elects to cure such alleged breach. In the event that Genus elects not to cure such alleged breach, Genus shall grant Poseida the right (but not the
obligation) to cure such alleged breach, and if Poseida elects to and does cure such breach, then Poseida may offset any such reasonable costs and expenses incurred by or on behalf of Poseida or any of its Affiliates in connection with curing such
breach against Poseida’s future payment obligations to Genus under this Agreement. 
 ARTICLE 3 

TECHNOLOGY TRANSFER; DEVELOPMENT AND COMMERCIALIZATION 

3.1    Transfer of Licensed Know-How. Genus will work with Poseida
in good faith in the [...***...] days after the Effective Date, and in the [...***...] days after expiration of the Option Period, to transfer to Poseida any and all Licensed Know-How in existence
as of the Effective Date and at the end of the Option Period, respectively, including all Antibody sequences therein or in the Licensed Patents that have not previously been disclosed to Poseida. 

3.2    Development and Commercialization of Licensed Products. As between the Parties, Poseida shall have
sole control, authority, and discretion over the research, development, manufacture and commercialization of Licensed Products in the Field in the Territory, subject to Section 3.3. 

 
 ***Certain Confidential Information Omitted 

  
 13. 

 3.3    Diligence. Poseida shall use Commercially
Reasonable Efforts to research, develop and commercialize at least one Licensed Cell Product in the Field in the Territory, whether alone or with or through one (1) or more Affiliates or Sublicensees. For purposes of this Section 3.3, the
efforts of each Affiliate or Sublicensee shall be considered efforts of Poseida. On or before the thirtieth day following the end of each Calendar Year of the Term prior to the First Commercial Sale of a Licensed Cell Product, Poseida shall provide
to Genus a written report describing the efforts by Poseida, or any Affiliates or Sublicensees, to meet the diligence requirements described in this Section 3.3. 

ARTICLE 4 

FINANCIAL TERMS 

4.1    Upfront Payment. Within ten (10) business days after the Effective Date, Poseida shall pay to
Genus a one-time upfront payment of One Million Five Hundred Thousand Dollars ($1,500,000). 

4.2    Option Exercise Fee. On that date on which Poseida exercises the Option pursuant to
Section 2.1(b), Poseida shall pay to Genus a one-time Option exercise fee of One Million Five Hundred Thousand Dollars ($1,500,000). 

4.3    Development, Regulatory and Sales Milestone Payments. Poseida shall promptly notify Genus, but in any
event within (a) [...***...] days after the first achievement of each of the first six (6) milestone events in the table below and (b) [...***...] days after the end of the Calendar Year in which each of the last three
(3) milestone events in the table below is achieved. Thereafter, Genus may invoice Poseida for the corresponding milestone payment, and Poseida shall pay such invoice within [...***...] days after receipt thereof. 

 

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 

  
 ***Certain Confidential Information
Omitted 

  
 14. 

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 
	 [...***...]
	  	$	[...***...]	 

 Each milestone payment set forth above shall be payable only once, regardless of the number of times the
applicable milestone event is achieved by any Licensed Cell Product or Licensed Products, as applicable, and regardless of the number of Licensed Cell Products or Licensed Products to achieve the applicable milestone event. Under no circumstances
shall Poseida be obligated to pay Genus more than seventy-one million Dollars ($71,000,000) under this Section 4.3. 

4.4    Royalties. 

(a)    Royalty Rates. Subject to Sections 4.4(b)-(c), Poseida shall pay to Genus royalties on Net Sales of
each Licensed Product during the applicable Royalty Term, with the applicable royalty to be calculated on a Related Licensed Product-by-Related Licensed Product basis
(as described below) by multiplying the applicable royalty rate by the corresponding amount of incremental Net Sales of the Related Licensed Products in the Field in the Territory in each Calendar Year. Solely for purposes of this Section 4.4,
a Licensed Cell Product will be considered different from another Licensed Cell Product if they contain CAR Cells that are different cell types or that are engineered to express different receptors. For each Licensed Cell Product, the Net Sales of
the related Licensed Companion Diagnostic, if any, will be combined together with the Net Sales of such Licensed Cell Product (each such Licensed Cell Product together with the related Licensed Companion Diagnostic, if any, are referred to together
as the “Related Licensed Products”) for purposes of determining the aggregate, worldwide Net Sales in the table below. 
  

					
	 Annual Net Sales of each Related Licensed Product in the
Territory
	  	Royalty Rate	 
	 [...***...]
	  	 	[...***...]%	 

  

***Certain Confidential Information Omitted 

  
 15. 

					
	 [...***...]
	  	 	[...***...]%	 
	 [...***...]
	  	 	[...***...]%	 
	 [...***...]
	  	 	[...***...]%	 

 (b)    Royalty Term. Royalties shall be paid under this Section 4.4, on
a country-by-country and Related Licensed Product-by-Related Licensed Product basis, on
Net Sales during the period of time beginning on the First Commercial Sale of such Related Licensed Product in such country and continuing until the later of: (i) the expiration of the last-to-expire Valid Claim of the Licensed Patents Covering the applicable Licensed Cell Product in the country of sale (a “Covering Claim” in such country for such Licensed Cell Product);
(ii) expiration of all Regulatory Exclusivity for such Licensed Cell Product in such country; and (iii) ten (10) years after the First Commercial Sale of such Licensed Cell Product in such country (the “Royalty Term”). 

(c)    Poseida may make the following reductions in the running royalties due to Genus in the event of the
following circumstances, provided that no single royalty payment to Genus for any Calendar Quarter will be reduced by more than [...***...] of the amounts that would have otherwise been due under Section 4.4(a): 

(i)    Know-How Reduction. In the event that, during the Royalty
Term for any Related Licensed Product and country, no Covering Claim exists for the corresponding Licensed Cell Product in such country, then the royalties payable under Section 4.4(a) on Net Sales of such Licensed Cell Product in such country
will be reduced by [...***...] for the remainder of such Royalty Term. Such royalty reduction will be calculated by determining the portion of total Net Sales of the relevant Related Licensed Product in a Calendar Quarter that is attributable
to the country in which such reduction applies, and by determining the total royalties for the Territory for such Related Licensed Product without reduction, and then reducing by [...***...] the applicable portion (based on Net Sales) of such
total royalties attributable to the country in which such reduction applies. 
  

***Certain Confidential Information Omitted 

  
 16. 

 (ii)    Third Party Intellectual Property. Poseida may
deduct from any royalties payable to Genus under Section 4.4(a), [...***...] of all consideration paid by Poseida or its Affiliates or Sublicensees for any rights to Third Party intellectual property used in the Licensed Cell Product
(including its development and manufacture) that is necessary to commercialize such Licensed Cell Product. Poseida may carry forward to subsequent calendar quarters any deductions that it was not able to deduct as a result of the proviso in the
first sentence of this Section 4.4(c). 
 ARTICLE 5 

PAYMENTS, RECORDS, AUDIT 

5.1    Payments. All amounts payable to Genus under this Agreement shall be paid in Dollars by check or by
wire transfer to a bank account specified in writing by Genus. 
 5.2    Reports. Within [...***...]
days after the end of each Calendar Quarter of any Calendar Year, following the First Commercial Sale of any Licensed Product during the Term, Poseida shall deliver to Genus a statement, on a country-by-country and Licensed Product-by-Licensed Product basis, of the following: 

(a)    a list of the Licensed Products manufactured and sold by Poseida, and any Affiliates or Sublicensees, on a country-by-country and Licensed Product-by-Licensed Product basis; 

(b)    the amount of gross sales and Net Sales of each of the Licensed Products during the applicable calendar quarter;

 (c)    the deductions applicable to calculating Net Sales (including if such Licensed Product is a Combination
Product); 
 (d)    an itemized accounting of the calculation of the amount of the royalty payment due on such Net Sales
for such calendar quarter, including (i) a description of any reductions under Section 4.4(c), and (ii) a revised calculation of the payment due after the application of such offsets. 

Along with such royalty report, Poseida shall pay Genus the royalties due for such Calendar Quarter. If no royalties are due, Poseida shall so report. 

After the date of First Commercial Sale in any country, Poseida shall deliver to Genus a summary within [...***...] months after such First Commercial
Sale providing the activities of Poseida, and any Affiliates and Sublicensees directed toward promoting the sale of Licensed Products in the Territory. 

5.3    Exchange Rate. For Net Sales outside the United States, the rate of exchange to be used in computing
the amount of currency equivalent in United States dollars shall be made at the rate of exchange published in the Wall Street Journal, Western Edition on the last business day of the applicable Calendar Quarter. 

 
 ***Certain Confidential Information Omitted 

  
 17. 

 5.4    Books and Records. Poseida shall keep accurate
books and accounts of record in connection with its sales of Licensed Products in sufficient detail to permit verification of Poseida’s payments pursuant to Sections 4.3 and 4.4. Poseida shall require its Affiliates and Sublicensees to keep
accurate books and accounts of records in connection with their sales of Licensed Products for which a royalty is due hereunder. Poseida shall maintain its records for a period of [...***...] years from the end of the calendar quarter in which
such sales occurred. 
 5.5    Audit. Genus or DFCI, [...***...], through an independent, nationally
recognized certified public accountant chosen by Genus or DFCI (and reasonably acceptable to Poseida), shall have the right to access Poseida’s relevant books and records for the sole purpose of verifying Poseida’s payments to Genus
pursuant to Section 4.3 and 4.4 during any portion or all of the preceding [...***...] years; such access shall be conducted after reasonable prior notice by Genus to Poseida during Poseida’s ordinary business hours, shall not be
more frequent than once during any calendar year and shall not include any books and records that were previously accessed pursuant to this Section 5.5. Such accountant shall execute a confidentiality agreement with Poseida in customary form
and shall only disclose to Genus or DFCI whether Poseida paid Genus the correct amounts pursuant to Section 4.3 or 4.4 during the audit period and if not, any information necessary to explain the source of the discrepancy. If such audit
determines that Poseida paid Genus less than the amount properly due and such determination is not subject to a good faith dispute, then Poseida shall promptly pay Genus an amount equal to such underpayment plus interest as set forth in
Section 5.7, and if the amount underpaid exceeds [...***...] of the amount actually due over the audited period, Poseida shall also reimburse Genus (or DFCI) for the reasonable costs of such audit (including the fees and expenses of the
certified public accountant). In the event such audit determines that Poseida paid Genus more than the amount properly due, then Genus shall promptly issue a refund to Poseida of such overpayment. Poseida shall require its Affiliates and
Sublicensees to make their records available for inspection by Genus or DFCI in accordance with this Section 5.5. 

5.6    Withholding of Taxes. Poseida shall pay all amounts payable to Genus under this Agreement in United
States funds [...***...] deduction for taxes, exchange, collection or other charges that may be imposed by any country or political subdivision with respect to any amounts payable to Genus under this Agreement as a result of any action of
Poseida or any successor in interest to Poseida. [...***...]. 
 5.7    Interest. Any payment owed
to Genus under this Agreement that is not made when due will accrue interest beginning on the first day following the due date specified in Article 4 and such interest payment will be due immediately but in no event later than the payment of the
overdue amount to Genus. The interest will be calculated at the annual rate of the sum of (a) [...***...] plus (b) [...***...], the interest being compounded on the last day of each Calendar Quarter; provided that the annual rate may not
exceed the maximum legal interest rate permitted by applicable Law. The payment of interest as required by this Section 5.7 does not foreclose or in any way limit Genus from exercising any other rights or remedies it has as a consequence of the
lateness of any payment. 
  
 ***Certain Confidential Information Omitted

  
 18. 

 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1    Ownership of Inventions. Ownership of Information, whether or not patentable, made in the course of
performing activities under this Agreement, including all intellectual property rights therein, shall be as follows: (a) Poseida shall own all Information made solely by employees, agents or independent contractors of Poseida, (b) Genus
shall own all Information made solely by employees, agents or independent contractors of Genus, and (c) the Parties shall jointly own all Information made jointly by employees, agents or independent contractors of each Party (“Joint
Inventions”). All Patents claiming patentable Joint Inventions shall be referred to herein as “Joint Patents”. Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement,
each Party shall be entitled to practice, grant licenses to, assign and exploit the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party. 

6.2    Prosecution of Patents. 

(a)    Licensed Patents. 

(i)    Subject to Section 6.2(a)(ii), Genus shall be responsible for and control the preparation, filing, prosecution
and maintenance of all patents and patent applications within the Licensed Patents, [...***...]; provided, however, that Genus shall, to the extent relevant to Licensed Cell Products in the Field in the Territory: (A) provide all
information reasonably requested by Poseida with respect to the Licensed Cell Patents, (B) promptly notify Poseida in writing with respect to all significant developments regarding the Licensed Cell Patents, (C) promptly provide Poseida
with a copy of each material communication from any patent authority regarding the Licensed Cell Patents, and (D) provide Poseida with drafts of each material filing (including draft patent applications and responses to office actions and
similar filings) with respect to the Licensed Cell Patents a reasonable amount of time in advance of the anticipated filing date and shall, prior to filing, consider Poseida’s reasonable comments in good faith. 

(ii)    In the event that Genus determines not to file, maintain or continue prosecution of any patent or patent
application within the Licensed Cell Patents, Genus shall provide Poseida written notice thereof at least [...***...] days before the applicable deadline. Upon receipt of such notice, Poseida shall have the right, but not the obligation, at
its expense, to assume responsibility for filing, prosecuting, and maintaining such patents and patent applications. If Poseida decides to assume such responsibility, in its sole discretion, it shall so notify Genus in writing. 

(iii)    As soon as practicable after receipt of the notice from Poseida described in Section 6.2(a)(ii), Genus
shall transfer the existing, complete patent files for all applicable patents and patent applications to Poseida, shall file all documents necessary to transfer correspondence with the U.S. Patent and Trademark Office and other applicable patent
authorities to Poseida and shall give Poseida’s patent counsel power of attorney thereto. Genus shall cooperate 
  

***Certain Confidential Information Omitted 

  
 19. 

 
with Poseida in the transfer of all prosecution and maintenance responsibilities relating to the Licensed Cell Patents. 

(b)    Joint Patents. 

(i)    Subject to Section 6.2(b)(ii), Poseida shall be responsible for and control the preparation, filing,
prosecution and maintenance of all patents and patent applications within the Joint Patents, [...***...]; provided, however, that Poseida shall (A) provide all information reasonably requested by Genus with respect to the Joint Patents,
(B) promptly notify Genus in writing with respect to all significant developments regarding the Joint Patents, (C) promptly provide Genus with a copy of each material communication from any patent authority regarding the Joint Patents, and
(D) provide Genus with drafts of each material filing (including draft patent applications and responses to office actions and similar filings) with respect to the Joint Patents a reasonable amount of time in advance of the anticipated filing
date and shall, prior to filing, consider Genus’ reasonable comments in good faith. 
 (ii)    In the event that
Poseida determines not to file, maintain or continue prosecution of any patent or patent application within the Joint Patents, Poseida shall provide Genus written notice thereof at least [...***...] days before the applicable deadline. Upon
receipt of such notice, Genus shall have the right, but not the obligation, at its expense, to assume responsibility for filing, prosecuting, and maintaining such patents and patent applications. If Genus decides to assume such
responsibility, in its sole discretion, it shall so notify Poseida in writing. 
 (iii)    As soon as practicable after
receipt of the notice from Genus described in Section 6.2(b)(ii), Poseida shall transfer the existing, complete patent files for all applicable patents and patent applications to Genus, shall file all documents necessary to transfer
correspondence with the U.S. Patent and Trademark Office and other applicable patent authorities to Genus and shall give Genus’ patent counsel power of attorney thereto. Poseida shall cooperate with Genus in the transfer of all prosecution and
maintenance responsibilities relating to the Joint Patents. 
 (c)    Cooperation. Each Party shall fully
cooperate with the other Party to execute all lawful papers and instruments and to make all rightful oaths and declarations as may be necessary or useful in the preparation and prosecution of the Licensed Cell Patents and Joint Patents. 

(d)    Poseida Patents. Poseida shall have the sole right to prepare, file, prosecute and maintain Patents that
claim Poseida’s solely-owned Information, at Poseida’s sole cost and expense. 
 6.3    Enforcement.

 (a)    Notification. If either Party becomes aware of any (i) existing or threatened infringement,
anywhere in the world, of any Licensed Cell Patent or Joint Patent, which infringement involves (A) the manufacture, use, sale, import or offer for sale of any Licensed Cell 

 
 ***Certain Confidential Information Omitted 

  
 20. 

 
Product or (B) the filing of a BLA by a Third Party for a product that names a Licensed Cell Product as a reference product (or similar filing in a country other than the U.S.) or
(ii) declaratory judgment action by a Third Party in connection with any infringement described in the preceding clause (i) alleging the invalidity, unenforceability or non-infringement of a Licensed
Cell Patent in the Field and in the Territory (collectively (i) and (ii), a “Product Infringement”), such Party shall promptly notify the other Party in writing to that effect. 

(b)    Enforcement Rights. 

(i)    Poseida shall have the first right, but not the obligation, to bring an appropriate suit or take other action
against any person or entity engaged in, or to defend against, such Product Infringement, [...***...]. If Poseida does not, within [...***...] days after its receipt or delivery of notice under Section 6.3(a), commence a suit to
enforce the applicable Patents, take other action to terminate such Product Infringement or initiate a defense against such Product Infringement, then Genus shall have the right, but not the obligation, to commence such a suit or take such an action
or defend against such Product Infringement in the Territory [...***...]. In such event, Poseida shall take appropriate actions in order to enable Genus to commence a suit or take the actions set forth in the preceding sentence, and Poseida
shall have the right [...***...], to be represented in any such suit by counsel of its own choice. 

(ii)    Genus may request Poseida to take steps to protect the Licensed Cell Patents from an apparent infringement.
Poseida shall notify Genus, within [...***...] months of receiving a written request from Genus, of action it intends to take, if any, to compel termination of the alleged infringing action or to initiate legal proceedings against the alleged
infringer. 
 (iii)    Genus and/or DFCI independently has the right to join any legal proceeding under this
Section 6.3(b), and fund up to [...***...] of the cost of the legal proceeding from the date of joining. If Genus and/or DFCI elects to join as a party to the action pursuant to this Section 6.3(b), Genus and/or DFCI may jointly
participate in the action with Poseida, but Poseida’s counsel will be lead counsel. 
 (iv)    Regardless of
whether Genus and/or DFCI are joined or join any legal proceeding initiated by Poseida, no settlement, consent judgment or other voluntary final disposition of the legal proceeding that adversely affects Genus and/or DFCI may be entered into without
the consent of Genus, which consent shall not be unreasonably withheld or delayed. 
 (c)    Collaboration. Each
Party shall cooperate with and provide to the Party enforcing any such rights under this Section 6.3 reasonable assistance in such enforcement, [...***...]. The non-enforcing Party further agrees to
join, [...***...], any such action brought under this Section 6.3 as a party plaintiff if required by applicable law to pursue such action. The enforcing Party under this Section 6.3 shall keep the other Party regularly informed of
the status and progress of such enforcement efforts, and shall reasonably consider the other Party’s comments on any such efforts. Poseida may exercise any of its rights pursuant to this Section 6.3 through an Affiliate or Sublicensee.

  
 ***Certain Confidential Information Omitted 

  
 21. 

 (d)    Expenses and Recoveries. The Party bringing or defending a
claim, suit or action under Section 6.3(b) shall be solely responsible for any expenses incurred by such Party as a result of such claim, suit or action. If such Party recovers monetary damages in such claim, suit or action, such recovery shall
be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation (including, for this purpose, a reasonable allocation of expenses of internal counsel), and any remaining amounts shall be allocated as follows:
[...***...]. 
 (e)    Enforcement of Poseida Patents. As between the Parties, Poseida shall have the sole
right, but not the obligation, to bring an appropriate suit or other action against any person or entity allegedly infringing any Patents owned or controlled by Poseida and to defend against any declaratory judgment action against any such Patents.

 (f)    DFCI. DFCI’s rights under this Section 6.3 are limited to the DFCI Patents and not any other
Licensed Patent. 
 6.4    Action by Third Party. In the event that any Third Party initiates a
declaratory judgment action alleging the noninfringement, invalidity or unenforceability of the DFCI Patents, or if any Third Party brings an infringement action against Poseida or its Affiliates or Sublicensees because of the exercise of the rights
granted Poseida under this Agreement with respect to the DFCI Patents, and Poseida, Genus and/or DFCI has not commenced any action to enforce DFCI Patents against such Third Party under the terms of Section 6.3 above, Poseida shall give prompt
notice to Genus of any such action. Within [...***...] days from the date of its notice to Genus of any action covered under this Section 6.4, Poseida shall notify Genus whether Poseida will defend against such action under its own
control [...***...]. Prior to its election of whether or not to defend the declaratory judgment action during this [...***...]day period, Poseida may, considering in good faith the views of Genus and DFCI, take any necessary actions,
including the filing of pleadings required by the Federal Rules of Civil Procedure or any local rules of court. Any such actions and filings during this [...***...] day pendency prior to election shall not be deemed as an election by Poseida
to defend the declaratory judgment action. If Poseida elects not to defend such action, Genus and/or DFCI shall have the right, but not the obligation to defend against such action under its own control [...***...]. Any owner of the applicable
DFCI Patents shall join the action as a party if required by law, [...***...]. Neither Party shall enter into any settlement, consent judgment or other voluntary final disposition of any action under this Section 6.4 without the other
Party’s prior written consent, which consent shall not be unreasonably withheld or delayed, unless the settlement includes any express or implied admission of liability or wrongdoing on Genus’ and DFCI’s part, in which case the right
to grant or deny consent is absolute and at its sole discretion. Notwithstanding the above, if Poseida and/or Genus has commenced any action to enforce DFCI 
  

***Certain Confidential Information Omitted 

  
 22. 

 Patents against such Third Party under the terms of Section 6.3 above, then the terms of
Section 6.3 will supersede the terms of this Section 6.4. 
 ARTICLE 7 

CONFIDENTIALITY 

7.1    Confidentiality. Each Party, in its capacity as a Receiving Party, agrees that, during the Term and
for a period of [...***...] years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or
the performance of any obligations hereunder) any Confidential Information furnished to it by the Disclosing Party pursuant to this Agreement, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties.
The foregoing confidentiality and non-use obligations shall not apply to any portion of Disclosing Party’s Confidential Information that the Receiving Party can demonstrate by competent written proof:

 (a)    was already known to the Receiving Party or its Affiliate, other than under an obligation of confidentiality,
at the time of disclosure by the Disclosing Party; 
 (b)    was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the Receiving Party; 
 (c)    became generally available to the
public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement; 

(d)    was disclosed to the Receiving Party or its Affiliate by a Third Party who has a legal right to make such
disclosure and who did not obtain such information directly or indirectly from the Disclosing Party; or 
 (e)    was
independently discovered or developed by the Receiving Party or its Affiliate without access to or aid, application or use of Disclosing Party’s Confidential Information, as evidenced by a contemporaneous writing. 

7.2    Authorized Disclosure. Notwithstanding the obligations set forth in Section 7.1, Receiving Party
may disclose Disclosing Party’s Confidential Information and the terms of this Agreement solely to the extent: 

(a)    such disclosure is reasonably necessary to (i) its Representatives on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are aware of the confidential nature of such
information and are bound by written obligations of confidentiality and non-use consistent with those contained in this Agreement; or (ii) actual or potential investors, acquirors, licensees and 

 
 ***Certain Confidential Information Omitted 

  
 23. 

 
other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, collaboration or license, provided that in each such
case such recipients are bound by confidentiality and non-use obligations at least as stringent as those contained in the Agreement and with a term of no less than [...***...] years; or 

(b)    such disclosure is reasonably necessary to comply with applicable Laws, including regulations promulgated by
applicable security exchanges, court order, administrative subpoena or order; provided that the Party subject to such Laws or other order shall (i) promptly notify the other Party of such required disclosure, (ii) use reasonable efforts to
obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure and (iii) disclose only that information that, at the advice of counsel, is required to be disclosed. 

Receiving Party will be responsible for any failure of its Representatives to comply with the terms of this Section 7.2. 

7.3    Publicity; Term of Agreement. 

(a)    The Parties agree that the material terms of this Agreement are the Confidential Information of both Parties,
subject to the special authorized disclosure provisions set forth in this Section 7.3 or Section 7.2. 

(b)    If either Party desires to make any public announcement concerning the material terms of this Agreement, such Party
shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval (except as otherwise provided herein), except that in the case of a press release or governmental filing
required by Law, the disclosing Party shall provide the other Party with such advance notice as it reasonably can and shall not be required to obtain approval therefor. Each such press release shall contain appropriate references to the other Party
if so requested. A Party commenting on such a proposed press release shall provide its comments, if any, within [...***...] business days after receiving the press release for review. Neither Party shall be required to seek the permission of
the other Party to repeat any information that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 7.3(b), provided such information remains accurate as of such time. 

(c)    The Parties acknowledge that either or both Parties may be obligated to file under applicable Laws a copy of this
Agreement with the U.S. Securities and Exchange Commission or other Governmental Authorities. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of the commercial terms and sensitive
technical terms hereof and thereof to the extent such confidential treatment is reasonably available to such Party. In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for
which such Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s reasonable comments thereon to the extent consistent with the legal requirements, with respect to the filing Party,
governing disclosure of material agreements and material information that must be publicly filed. 
  

***Certain Confidential Information Omitted 

  
 24. 

 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1    Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party
as follows: 
 (a)    Corporate Existence. As of the Effective Date, it is a company or corporation duly
organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated. 

(b)    Corporate Power, Authority and Binding Agreement. As of the Effective Date, (i) it has the corporate
power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the
performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance
with its terms. 
 8.2    Additional Representations and Warranties of Genus. Genus represents and
warrants and, as applicable, covenants to Poseida as follows, as of the Effective Date: 
 (a)    Title;
Encumbrances. Genus is the sole owner or exclusive licensee of all Licensed Patents (which ownership or license is identified on Exhibit A), free and clear from any mortgages, pledges, liens, security interests, conditional and
installment sale agreements, encumbrances, charges or claims of any kind that would have an adverse impact on the rights and licenses granted under this Agreement. Genus has the full and legal rights and authority to license to Poseida the Licensed
Technology as provided herein; 
 (b)    Exhibit A. To Genus’ Knowledge, Exhibit A is an
accurate listing by owner, inventor(s), serial number, country and status of all patents and patent applications owned or controlled by Genus as of the Effective Date that are necessary or useful for the development, manufacture, use, offer for
sale, sale or import of CAR Cells; 
 (c)    Validity. To the actual knowledge of [...***...]. as of
the Effective Date without any duty of due inquiry (“Genus’ Knowledge” or “Knowledge”), there is no fact or circumstance existing as of the Effective Date that would cause Genus to reasonably conclude that any
of the issued patents in the Licensed Patents is invalid or unenforceable, or that any patent application in the Licensed Patents will be invalid or unenforceable upon issuance; 

(e)    Notice of Infringement. Genus has not received any written notice or written threat from any Third
Party asserting or alleging, nor does Genus have any Knowledge of any basis for any assertion or allegation, that any research, manufacture or development of Antibodies by Genus prior to the Effective Date infringed or would infringe the
intellectual property rights of such Third Party; 
  
 ***Certain
Confidential Information Omitted 

  
 25. 

 (f)    Notice of Misappropriation. Genus has not received
any written notice or written threat from any Third Party asserting or alleging, and to Genus’ Knowledge there is no basis for any assertion or allegation, that any research, manufacture or development of the Licensed Technology, including
Antibodies, by Genus prior to the Effective Date misappropriated the intellectual property rights of such Third Party; 

(g)    No Conflicts. Genus has not entered, and shall not enter, into any agreement with any Third Party
that is in conflict with the rights granted to Poseida under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting the rights granted to Poseida under this Agreement, or that would otherwise
materially conflict with or adversely affect Poseida’s rights under this Agreement; 
 (h)    Third Party
Technology. To Genus’ Knowledge, (i) the manufacture, development and commercialization of CAR Cells will not infringe or misappropriate any intellectual property rights of a Third Party, and (ii) there are no pending Third Party
patent applications that, if issued with the published or currently pending claims, would be infringed by the manufacture, development or commercialization of CAR Cells; 

(i)    Third Party Infringement. To Genus’ Knowledge, no Third Party is infringing or has infringed any
Licensed Patents or has misappropriated any Licensed Know-How; 

(j)    Disclosure. Genus has disclosed to Poseida all information in Genus’s possession or Control that
to Genus’ Knowledge would be material to Poseida’s analysis of the rights and licenses granted under this Agreement, and all such information disclosed by Genus is true and correct to Genus’ Knowledge. 

(k)    DFCI Agreement. (i) Neither Genus nor, to Genus’ Knowledge, DFCI is in breach of the DFCI
Agreement and, to Genus’ Knowledge, the DFCI Agreement is in full force and effect, and neither Genus nor any of its Affiliates has received any written notice of breach of the DFCI Agreement; and (ii) a true, correct and complete copy of
the DFCI Agreement has been provided to Poseida. 
 8.3    Disclaimers. EXCEPT AS OTHERWISE SET FORTH IN
THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY HEREBY DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, ORAL OR WRITTEN, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING
WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT AND ANY WARRANTY ARISING OUT OF PRIOR COURSE OF DEALING AND USAGE OF TRADE. 

8.4    Covenant Regarding Control. Genus Controls and shall Control throughout the Term (a) all Patents
owned or licensed by Genus as of the Effective Date and (b) any Patents that become owned or licensed by Genus after the Effective Date during the Term; in each case of (a) and (b), that are necessary for the development, manufacture, use,
offer for sale, sale or import of 

  
 26. 

 
CAR Cells; provided, however, that this Section 8.4 will not affect transfer of such Patents to any Third Party to which this Agreement is assigned pursuant to Section 12.10. 

ARTICLE 9 

INDEMNIFICATION 

9.1    Indemnification by Poseida. Poseida shall defend, indemnify, and hold Genus, its Affiliates
and DFCI, and each of their respective officers, directors, employees, and agents (the “Genus Indemnitees”) harmless from and against damages or other amounts payable to a Third Party claimant, as well as any reasonable
attorneys’ fees and costs of litigation incurred by such Genus Indemnitees, resulting from any claims, suits, proceedings or causes of action brought by such Third Party (collectively, “Claims”) against such Genus Indemnitee to
the extent arising from or based on (a) the research, development, design, production, manufacture, sale, commercialization, use in commerce, lease, promotion or other exploitation of any Licensed Products) by or on behalf of Poseida or its
Affiliates or Sublicensees, (b) the breach of any of Poseida’s obligations, representations or warranties under this Agreement, (c) the willful misconduct or negligent acts of Poseida, its Affiliates, or Sublicensees, or their
respective officers, directors, employees or agents or (d) any activities carried out by Poseida, its Affiliates, or Sublicensees, or their respective officers, directors, employees or agents pursuant to this Agreement or the exercise by
Poseida, its Affiliates, or Sublicensees, or their respective officers, directors, employees or agents of any rights granted under this Agreement. The foregoing indemnity obligation shall not apply to the extent that (i) the Genus Indemnitees
fail to comply with the indemnification procedures set forth in Section 9.3 and Poseida’s defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any activity set forth in
Section 9.2(b) or 9.2(c) for which Genus is obligated to indemnify the Poseida Indemnitees under Section 9.2. 

9.2    Indemnification by Genus. Genus shall defend, indemnify, and hold Poseida and its Affiliates and
their respective officers, directors, employees, and agents (the “Poseida Indemnitees”) harmless from and against damages or other amounts payable to a Third Party claimant, as well as any reasonable attorneys’ fees and costs
of litigation incurred by such Poseida Indemnitees, resulting from any Claims against such Poseida Indemnitee to the extent arising from or based on (a) the research, development, design, production, manufacture, sale, commercialization, use in
commerce, lease, promotion or other exploitation of any products containing Antibodies by or on behalf of Genus or its Affiliates or licensees, (b) the breach of any of Genus’ obligations, representations or warranties under this
Agreement, or (c) the willful misconduct or negligent acts of Genus or its Affiliates, or the officers, directors, employees or agents of Genus or its Affiliates. The foregoing indemnity obligation shall not apply to the extent that
(i) the Poseida Indemnitees fail to comply with the indemnification procedures set forth in Section 9.3 and Genus’ defense of the relevant Claims is prejudiced by such failure, or (ii) any Claim arises from or is based on any
activity set forth in Section 9.1(b) or 9.1(c) for which Poseida is obligated to indemnify the Genus Indemnitees under Section 9.1. 

9.3    Procedure. To be eligible to be indemnified as described in this Article 9, each person or entity
seeking to be indemnified (each, an “Indemnitee”) shall provide the indemnifying 

  
 27. 

 
Party with prompt notice of any claim (with a description of the claim and the nature and amount of any such loss) giving rise to the indemnification obligation pursuant to Section 9.1 or
9.2, as the case may be, and the exclusive ability to defend such claim (with the reasonable cooperation of Indemnitee(s)). Each Indemnitee shall have the right to retain its own counsel, at its own expense, if representation by the counsel of the
indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnitee(s) and the Indemnifying Party. Neither the Indemnitee(s) nor the indemnifying Party shall settle or consent to the entry of any judgment
with respect to any claim for losses for which indemnification is sought without the prior written consent of the other (not to be unreasonably withheld or delayed); provided however, that the indemnifying Party shall have the right to settle or
compromise any claim for losses without such prior written consent if the settlement or compromise provides for a full and unconditional release of the Indemnitee(s) and is not materially prejudicial to any Indemnitee’s rights. 

9.4    Insurance. Each Party shall procure and maintain general liability insurance, including product
liability insurance, in amounts not less than $[...***...] per incident and $[...***...] annual aggregate at all times during which any Licensed Product (in the case of Poseida) or Antibody (in the case of Genus) is being clinically
tested in human subjects or commercially distributed or sold by such Party and for the [...***...] year period thereafter. Each Party shall list DFCI as an additional insured. It is understood that such insurance shall not be construed to
create a limit of either Party’s liability with respect to its indemnification obligations under this Article 9. Each Party shall provide the other Party with written evidence of such insurance upon request. Each Party shall provide the other
Party with written notice at least [...***...] days prior to the cancellation or non-renewal of such insurance. Poseida shall require any Affiliates or Sublicensee(s) to maintain insurance in favor of
DFCI and trustees, officers, medical and professional staff, employees, and agents and their respective successors, heirs and assigns under the same terms set forth in this Section 9.4. 

ARTICLE 10 

TERM; TERMINATION 

10.1    Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated
pursuant to this Article 10, shall remain in effect on a Licensed Cell Product-by-Licensed Cell Product and country-by-country basis, until the expiration of the Royalty Term for such Licensed Cell Product in such country (the “Term”). Upon the expiration of the Royalty Term for a Licensed Cell
Product in a particular country, the licenses granted by Genus to Poseida under Section 2.1 with respect to such Licensed Cell Product and any related Licensed Companion Diagnostic, shall become fully-paid, royalty free, perpetual and
irrevocable for such country. 
 10.2    Termination by Poseida. Poseida may terminate this Agreement at
will upon thirty (30) days prior written notice to Genus. 
 10.3    Termination for Certain Reasons. 

(a)    Breach. Subject to Section 10.3(b), each Party shall have the right to terminate this Agreement upon
written notice to the other Party if such other Party materially 
  

***Certain Confidential Information Omitted 

  
 28. 

 
breaches this Agreement and, after receiving written notice from the non-breaching Party identifying such material breach in reasonable detail, fails to
cure such material breach within ninety (90) days from the date of such notice; provided that if such breach is not reasonably capable of cure within such ninety (90)-day period, the breaching Party may
submit a reasonably acceptable cure plan prior to the end of such ninety (90)-day period, in which case the other Party shall not have the right to terminate this Agreement for so long as the breaching Party
is using diligent and good faith efforts to implement such cure plan and cure such breach. 
 (b)    Disputed
Breach. If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party in accordance with Section 10.3(a), and such alleged breaching Party provides the other
Party notice of such dispute within such ninety (90)-day period, then the non-breaching Party shall not have the right to terminate this Agreement under
Section 10.3(a) unless and until the arbitrator, in accordance with Article 11, has determined that the alleged breaching Party has materially breached the Agreement and such Party fails to cure such breach within ninety (90) days
following such arbitrator’s decision. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their
respective obligations hereunder. This Section 10.3(b) will not apply with respect to any act or omission by Poseida that would reasonably be deemed a breach of the DFCI Agreement, and in such event the provisions of Section 9.2.8 of the
DFCI Agreement shall apply, mutatis mutandis as if Genus is DFCI and Poseida is Company. 

(c)    Insolvency. Genus may terminate this Agreement immediately upon written notice, with no further notice
obligation or opportunity to cure, if (i) Poseida makes an assignment for the benefit of creditors; (ii) Poseida admits in writing its inability to pay debts as they mature; (iii) a trustee or receiver is appointed for a substantial
part of Poseida’s assets; or (iv) a bankruptcy proceeding (other than a reorganization proceeding in which Poseida is and will continue to be in compliance with all the terms of this Agreement) is instituted against Poseida which is
acquiesced in, is not dismissed within one hundred twenty (120) days, or results in an adjudication of bankruptcy. 

(d)    Other Causes. Genus may terminate this Agreement immediately upon written notice to Poseida if Poseida (or
an Affiliate or Sublicensee) fails to initiate a Phase I clinical trial for a Licensed Product within twenty (20) months after receiving approval of an IND filed by Poseida (or such Affiliate or Sublicensee) with respect to such Licensed
Product. 
 10.4    Effects of Termination. 

(a)    Accrued Obligations; Survival. Termination or expiration of this Agreement for any reason shall not release a
Party from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereto to the extent it is expressly stated to survive such termination. The following provisions shall
survive any expiration or termination of this Agreement for a period of time specified therein, or if not specified, then they shall survive indefinitely: Articles 1, 7, 9, 11, and 12, and Sections 5.4, 5.5, 5.6, 5.7, 6.1, 8.3 and 10.4. 

  
 29. 

 (b)    Sublicense Survival. Upon termination of this Agreement by
Genus pursuant to Section 10.3, any sublicense granted by Poseida under this Agreement shall survive as a direct license between Genus and such Sublicensee on the same terms and conditions as those set forth in this Agreement, to the extent
applicable to the rights granted by Poseida to such Sublicensee, provided that such sublicense was granted in accordance with the terms of Section 2.2, and that such Sublicensee is in compliance with the terms of the sublicense agreement at the
time of such termination and agrees to comply with all applicable terms of this Agreement. Genus is not obligated or required to accept any terms or conditions that would bind Genus beyond the scope of this Agreement. 

ARTICLE 11 

GOVERNING LAW; DISPUTE RESOLUTION 

11.1    Governing Law. This Agreement shall be governed by the laws of the State of Delaware, without giving
effect to any conflicts of laws principles that would require the application of other law. 
 11.2    Dispute
Resolution. The Parties recognize that disputes as to matters arising under or relating to this Agreement or either Party’s rights or obligations hereunder may arise from time to time. It is the objective of the Parties to establish
procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 11 to
resolve any such dispute if and when it arises. 
 11.3    Resolution by Executives. If an unresolved
dispute as to matters arising under or relating to this Agreement or either Party’s rights or obligations hereunder arises, either Party may refer such dispute to the Chief Executive Officer of Genus and the Chief Executive Officer of Poseida,
who shall meet in person or by telephone within [...***...] days after such referral to attempt in good faith to resolve such dispute. If such matter cannot be resolved by discussion of such officers within such
[...***...]-day period (as may be extended by mutual written agreement), such dispute shall be resolved in accordance with Section 11.4. The Parties acknowledge that discussions between the Parties
to resolve disputes are settlement discussions under applicable rules of evidence and without prejudice to either Party’s legal position. 

11.4    Arbitration. 

(a)    JAMS. Any dispute that is not resolved through negotiations under Section 11.3 shall be finally settled
by binding arbitration before one arbitrator. The arbitration shall be administered by JAMS pursuant its Comprehensive Arbitration Rules and Procedures then in effect (the “JAMS Rules”), except as otherwise provided herein. The
seat, or legal place, of arbitration shall be Chicago, Illinois, and the Parties consent to the personal jurisdiction of the U.S. federal courts for any case arising out of or otherwise related to this arbitration, its conduct and its enforcement.
The language of the arbitration shall be English. The Parties acknowledge that this Agreement evidences a transaction involving interstate commerce. Notwithstanding Section 11.1 with respect to the applicable substantive Law, any arbitration
conducted pursuant to the terms of 
  
 ***Certain Confidential
Information Omitted 

  
 30. 

 
this Agreement shall be governed by the U.S. Federal Arbitration Act, 9 U.S.C. §§ 1-16 (the “Federal Arbitration Act”), to the
exclusion of any inconsistent state laws. 
 (b)    Award. Any award shall be promptly paid in Dollars free of
any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by Law, be charged against the Party resisting enforcement. Each Party agrees to abide by the award rendered in any
arbitration conducted pursuant to this Section 11.4, and agrees that, subject to the Federal Arbitration Act, judgment may be entered upon the final award in any court of competent jurisdiction, and the Parties intend all such courts to give
full faith and credit to such judgment in order to enforce such award. Judgment on the award may also be entered in any other court of competent jurisdiction. The award shall include interest from the date of any damages incurred for breach of this
Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator. 
 (c)    Costs.
Each Party shall bear its own legal fees. The arbitrator shall assess his or her costs, fees and expenses against the Party losing the arbitration unless he or she believes that neither Party is the clear winner, in which case the arbitrator shall
divide his or her fees, costs and expenses according to his or her sole discretion. The arbitrator, in the arbitrator’s discretion, may award reimbursement of attorney’s fees to the prevailing party. 

(d)    Injunctive Relief. Provided a Party has made a sufficient showing under the rules and standards set forth in
the U.S. Federal Rules of Civil Procedure and applicable case law, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by, injunctive measures after either Party submits in writing for arbitration claims requiring
immediate relief. Additionally, nothing in this Section 11.4 will preclude either Party from seeking interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other
interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. 

(e)    Confidentiality. The existence and content of the arbitral proceeding, including any rulings or award, shall
be kept confidential by the Parties and the arbitrator except to the extent (i) required by applicable Law; (ii) required to protect or pursue a legal right; (iii) required to enforce or challenge an award; or (iv) approved by
written consent of the Parties. Notwithstanding anything to the contrary herein, either Party may disclose matters relating to the arbitration or the arbitral proceedings where necessary for the preparation or presentation of a claim or defense in
such arbitration. The arbitrator shall issue appropriate protective orders to safeguard each Party’s Confidential Information. 

(f)    Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after
termination of this Agreement for any reason. 
 (g)    Patent and Trademark Disputes. Any dispute, controversy
or claim relating to the scope, validity, enforceability or infringement of any patents or trademarks shall be submitted to a court of competent jurisdiction in the country in which such patent or trademark rights were granted or arose. 

  
 31. 

 ARTICLE 12 

GENERAL PROVISIONS 

12.1    Rights in Bankruptcy. All licenses and other rights granted under or pursuant to this Agreement by
Genus are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree
that Poseida, as licensee of certain rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. 

12.2    Notices. Any notice required or permitted to be given under this Agreement shall be in writing,
shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 12.2, and shall be
deemed to have been given for all purposes when received, if hand-delivered or sent by reputable courier service. 
 All notices to Poseida shall be
addressed as follows: 
 Poseida Therapeutics, Inc. 

4242 Campus Point Court, Suite 700 

San Diego, CA 92121 

Attn: Mark Gergen, CBO and CFO 

with a copy to (which copy shall not constitute notice): 

Cooley LLP 

One Freedom Square 

Reston Town Center 

11951 Freedom Drive 

Reston, VA 20190-5656 

Attention: Ken Krisko 
 All
notices to Genus shall be addressed as follows: 
 Genus Oncology, LLC 

650 Albany Street 

Boston, MA 02118 

Attn: Nick Pontikes, CEO 

  
 32. 

 with a copy to (which copy shall not constitute notice): 

McDermott Will & Emery LLP 

28 State Street 

Boston, MA 02109-1775 

Attn: Sarah Hogan 
 Any Party
may, by written notice to the other, designate a new address to which notices to the Party giving the notice shall thereafter be delivered. 

12.3    Force Majeure. No Party shall be liable for any delay or failure of performance to the extent such
delay or failure is caused by circumstances beyond its reasonable control and that by the exercise of due diligence it is unable to prevent, provided that the Party claiming excuse uses its commercially reasonable efforts to overcome the same. 

12.4    Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder
through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with
such performance. 
 12.5    Further Actions. Each Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

12.6    Entirety of Agreement. This Agreement, including its Exhibits, sets forth the entire agreement and
understanding of the Parties relating to the subject matter contained herein and merges all prior discussions and agreements between them (including the Confidentiality Agreement) related to such subject matter. The Agreement may be amended only by
a written instrument signed by authorized representatives of each of the Parties. 
 12.7    Non-Waiver. The failure of a Party in any one or more instances to insist upon strict performance of any of the terms and conditions of this Agreement shall not be construed as a waiver or relinquishment, to any
extent, of the right to assert or rely upon any such terms or conditions on any future occasion. 

12.8    Independent Contractors. Each Party shall act solely as an independent contractor, and nothing in
this Agreement shall be construed to give either Party the power or authority to act for, bind or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture
partners between the Parties. 
 12.9    Severability. If any one or more of the provisions of this
Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions
hereof. The Parties shall make a good faith effort to replace 

  
 33. 

 
any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

12.10    Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations
hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party’s consent to its Affiliates or to a Third Party successor to substantially all of the business of such
Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either
Party in violation of the terms of this Section 12.10 shall be null, void and of no legal effect. 

12.11    Limitation of Liability. EXCEPT FOR INDEMNITY OBLIGATIONS IN ARTICLE 9 AND DAMAGES AVAILABLE FOR
BREACH OF ARTICLE 7, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE OR SPECIAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, EVEN IF
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 12.12    No Strict Construction; Headings. This Agreement
has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the
ambiguous provision. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or
Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word “or” is used in the inclusive sense (and/or). The term “including” as used herein means including,
without limiting the generality of any description preceding such term. 
 12.13    Counterparts. This
Agreement may be executed in one or more counterparts, each of which shall be an original and all of which shall constitute together the same document. 

Signature Page to Follow 

  
 34. 

 IN WITNESS WHEREOF, the Parties hereto
have duly executed this License Agreement on the Effective Date. 
  

									
	POSEIDA THERAPEUTICS, INC.	 		 	GENUS ONCOLOGY, LLC
			
	               /s/ Mark
Gergen
	 		 	               /s/
Nick Pontikes

				
	Name:	 	Mark Gergen	 	            	 	Name: Nick Pontikes
	Title:	 	CBO and CFO	 		 	Title: CEO

 Exhibits 
 Exhibit
A       Licensed Patents 
 Exhibit B       DFCI Agreement 

Signature Page of License Agreement 

 Exhibit A 

Licensed Patents 
 [...***...] 

 
 ***Certain Confidential Information Omitted 

  
 A-1 

 Exhibit B 

DFCI Agreement 
 [...***...] 

 
 ***Certain Confidential Information Omitted 

  
 B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]